 |
| Product Information |
Product Name: | Val-cit-PAB-OH |
Synonyms: | (S)-2-((R)-2-amino-3-methylbutanamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide;EOS-61316;(S)-2-((S)-2-amino-3-methylbutanamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide;L-Ornithinamide, L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-;Val-cit-PAB-OH;L-Valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide;NH2-Val-Cit-PAB;(D)-VAL-CIT-PAB |
CAS: | 159857-79-1 |
MF: | C18H29N5O4 |
MW: | 379.45 |
EINECS: | 826-617-2 |
| Val-Cit-PAB-OH – Cathepsin B Cleavable Linker for ADC Development |
Val-Cit-PAB-OH (CAS 159857-79-1) is a widely used antibody-drug conjugate linker designed for targeted cancer therapy. As a cathepsin B cleavable linker, it offers high selectivity in tumor environments, making it a preferred ADC linker in modern biopharmaceutical research. Available as high purity Val-Cit-PAB-OH (≥98%), this intermediate plays a key role in ADC synthesis and is an essential precursor for MC-Val-Cit-PAB production.
| Production & Manufacturing Process |
Our Val-Cit-PAB-OH is manufactured under GMP pharmaceutical intermediates standards with a focus on stability, reproducibility, and scalability:
Raw Material Selection: Pharmaceutical-grade amino acid derivatives ensure consistent quality.
Peptide Synthesis: Solid-phase peptide synthesis (SPPS) methods are employed to produce the Val-Cit-PAB sequence with high precision.
PAB Integration: The para-aminobenzyl (PAB) moiety is carefully introduced for self-immolative drug release upon cleavage.
Purification & QC: Advanced chromatographic purification ensures ≥98% purity, with full analytical documentation (HPLC, NMR, MS).
Scalability: Custom batch sizes and CDMO contract manufacturing for pharmaceutical intermediates available to support R&D and commercial needs.
| Applications & Benefits |
Antibody-Drug Conjugates (ADCs):
Functions as a Val-Cit-PAB-OH cathepsin B cleavable peptide linker, enabling selective drug release in tumor microenvironments.
MC-Val-Cit-PAB Precursor:
Serves as a Val-Cit-PAB-OH precursor for MC-Val-Cit-PAB production, widely applied in next-generation ADC therapies.
Targeted Drug Delivery:
Enhances therapeutic index by minimizing systemic toxicity and improving intracellular payload release.
Pharmaceutical R&D:
A key pharmaceutical intermediate CDMO solution for biotech companies developing oncology pipelines.
| Why Partner With Us? |
Specialized expertise in ADC linker synthesis
Flexible cdmo contract manufacturing for pharmaceutical intermediates
High batch-to-batch reproducibility and analytical support
Custom packaging and global logistics for research and industrial-scale supply
Val-Cit-PAB-OH is a cornerstone in modern ADC technology, enabling precise antibody-drug conjugate linker strategies for cancer therapeutics. With guaranteed ≥98% purity, regulatory-compliant production, and scalable CDMO support, it is an ideal choice for global pharmaceutical innovators.
| Product Information |
Product Name: | Val-cit-PAB-OH |
Synonyms: | (S)-2-((R)-2-amino-3-methylbutanamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide;EOS-61316;(S)-2-((S)-2-amino-3-methylbutanamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide;L-Ornithinamide, L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-;Val-cit-PAB-OH;L-Valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide;NH2-Val-Cit-PAB;(D)-VAL-CIT-PAB |
CAS: | 159857-79-1 |
MF: | C18H29N5O4 |
MW: | 379.45 |
EINECS: | 826-617-2 |
| Val-Cit-PAB-OH – Cathepsin B Cleavable Linker for ADC Development |
Val-Cit-PAB-OH (CAS 159857-79-1) is a widely used antibody-drug conjugate linker designed for targeted cancer therapy. As a cathepsin B cleavable linker, it offers high selectivity in tumor environments, making it a preferred ADC linker in modern biopharmaceutical research. Available as high purity Val-Cit-PAB-OH (≥98%), this intermediate plays a key role in ADC synthesis and is an essential precursor for MC-Val-Cit-PAB production.
| Production & Manufacturing Process |
Our Val-Cit-PAB-OH is manufactured under GMP pharmaceutical intermediates standards with a focus on stability, reproducibility, and scalability:
Raw Material Selection: Pharmaceutical-grade amino acid derivatives ensure consistent quality.
Peptide Synthesis: Solid-phase peptide synthesis (SPPS) methods are employed to produce the Val-Cit-PAB sequence with high precision.
PAB Integration: The para-aminobenzyl (PAB) moiety is carefully introduced for self-immolative drug release upon cleavage.
Purification & QC: Advanced chromatographic purification ensures ≥98% purity, with full analytical documentation (HPLC, NMR, MS).
Scalability: Custom batch sizes and CDMO contract manufacturing for pharmaceutical intermediates available to support R&D and commercial needs.
| Applications & Benefits |
Antibody-Drug Conjugates (ADCs):
Functions as a Val-Cit-PAB-OH cathepsin B cleavable peptide linker, enabling selective drug release in tumor microenvironments.
MC-Val-Cit-PAB Precursor:
Serves as a Val-Cit-PAB-OH precursor for MC-Val-Cit-PAB production, widely applied in next-generation ADC therapies.
Targeted Drug Delivery:
Enhances therapeutic index by minimizing systemic toxicity and improving intracellular payload release.
Pharmaceutical R&D:
A key pharmaceutical intermediate CDMO solution for biotech companies developing oncology pipelines.
| Why Partner With Us? |
Specialized expertise in ADC linker synthesis
Flexible cdmo contract manufacturing for pharmaceutical intermediates
High batch-to-batch reproducibility and analytical support
Custom packaging and global logistics for research and industrial-scale supply
Val-Cit-PAB-OH is a cornerstone in modern ADC technology, enabling precise antibody-drug conjugate linker strategies for cancer therapeutics. With guaranteed ≥98% purity, regulatory-compliant production, and scalable CDMO support, it is an ideal choice for global pharmaceutical innovators.
